Brief: FDA Accepts Viatris Supplemental New Drug Application For Mr-141 (Phentolamine Ophthalmic Solution 0.75%) For The Treatment Of Presbyopia
25/02/2026 12:00
Feb 25 (Reuters) - Viatris Inc VTRS.O: FDA ACCEPTS VIATRIS SUPPLEMENTAL NEW DRUG APPLICATION FOR MR-141 (PHENTOLAMINE OPHTHALMIC SOLUTION 0.75%) FOR THE TREATMENT OF PRESBYOPIA VIATRIS INC - FDA PDUFA GOAL DATE SET FOR OCTOBER 17, 2026 Source text: ID:nPn1vWfGFa Further company coverage: VTRS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Viatris
See all newsBrief: Viatris Receives U.S. FDA Approval For Ryzumvi® For The Treatment Of Presbyopia
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Deals of the day-Mergers and acquisitions
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal